Adjuvant Aromatase Inhibitor Therapy in Patients with Stage I Breast Cancer at a Regional Oncology Center in Israel: Implementation of a ‘Switching' Policy in Postmenopausal Patients after Initial Tamoxifen

Publisher： Karger

E-ISSN： 1423-0232|85|3|145-152

ISSN： 0030-2414

Source： Oncology, Vol.85, Iss.3, 2013-08, pp. : 145-152

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer

By Ligibel Jennifer A   Winer Eric P  

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 89-97

Future Medicine

Access to resources Recommend Favorite

Effect of Adjuvant Tamoxifen Therapy on Thyroid Function in Postmenopausal Women with Breast Cancer

By  

Oncology, Vol. 56, Iss. 1, 1999-01 ,pp. : 43-45

Karger

Access to resources Recommend Favorite

Eligibility, Compliance and Persistence of Sequential Therapy with Aromatase Inhibitors following 2–3 Years of Tamoxifen in Endocrine Adjuvant Breast Cancer Therapy

By  

Oncology, Vol. 81, Iss. 3-4, 2011-10 ,pp. : 151-157

Karger

Access to resources Recommend Favorite

Adjuvant endocrine therapy for postmenopausal women with early stage breast cancer

By Grant Margaret   Rea Daniel W  

Therapy, Vol. 1, Iss. 2, 2004-11 ,pp. : 305-318

Future Medicine

Access to resources Recommend Favorite

Physical activity and survival of postmenopausal, hormone receptor–positive breast cancer patients: Results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study

By  

CANCER, Vol. 120, Iss. 18, 2014-09 ,pp. : 2847-2854

John Wiley & Sons Inc

Access to resources Recommend Favorite